These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 27874234)

  • 21. Tetra-substituted imidazoles as a new class of inhibitors of the p53-MDM2 interaction.
    Vaupel A; Bold G; De Pover A; Stachyra-Valat T; Lisztwan JH; Kallen J; Masuya K; Furet P
    Bioorg Med Chem Lett; 2014 May; 24(9):2110-4. PubMed ID: 24704029
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction.
    Ding K; Lu Y; Nikolovska-Coleska Z; Wang G; Qiu S; Shangary S; Gao W; Qin D; Stuckey J; Krajewski K; Roller PP; Wang S
    J Med Chem; 2006 Jun; 49(12):3432-5. PubMed ID: 16759082
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery of highly potent p53-MDM2 antagonists and structural basis for anti-acute myeloid leukemia activities.
    Huang Y; Wolf S; Beck B; Köhler LM; Khoury K; Popowicz GM; Goda SK; Subklewe M; Twarda A; Holak TA; Dömling A
    ACS Chem Biol; 2014 Mar; 9(3):802-11. PubMed ID: 24405416
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rapid screening of protein-protein interaction inhibitors using the protease exclusion assay.
    Nirantar SR; Li X; Siau JW; Ghadessy FJ
    Biosens Bioelectron; 2014 Jun; 56():250-7. PubMed ID: 24508816
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Meeting Organocatalysis with Drug Discovery: Asymmetric Synthesis of 3,3'-Spirooxindoles Fused with Tetrahydrothiopyrans as Novel p53-MDM2 Inhibitors.
    Wang S; Jiang Y; Wu S; Dong G; Miao Z; Zhang W; Sheng C
    Org Lett; 2016 Mar; 18(5):1028-31. PubMed ID: 26883465
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Small molecule protein-protein inhibitors for the p53-MDM2 interaction.
    Dudkina AS; Lindsley CW
    Curr Top Med Chem; 2007; 7(10):952-60. PubMed ID: 17508926
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discovery of potent and selective spiroindolinone MDM2 inhibitor, RO8994, for cancer therapy.
    Zhang Z; Ding Q; Liu JJ; Zhang J; Jiang N; Chu XJ; Bartkovitz D; Luk KC; Janson C; Tovar C; Filipovic ZM; Higgins B; Glenn K; Packman K; Vassilev LT; Graves B
    Bioorg Med Chem; 2014 Aug; 22(15):4001-9. PubMed ID: 24997575
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discovery of Potent and Selective p53-MDM2 Protein-Protein Interaction Inhibitors as Anticancer Drugs.
    Holzer P
    Chimia (Aarau); 2017 Oct; 71(10):716-721. PubMed ID: 29070416
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Design, synthesis and biological evaluation of novel 3,4,5-trisubstituted aminothiophenes as inhibitors of p53-MDM2 interaction. Part 2.
    Wang W; Lv D; Qiu N; Zhang L; Hu C; Hu Y
    Bioorg Med Chem; 2013 Jun; 21(11):2886-94. PubMed ID: 23611770
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Selective and potent morpholinone inhibitors of the MDM2-p53 protein-protein interaction.
    Gonzalez AZ; Eksterowicz J; Bartberger MD; Beck HP; Canon J; Chen A; Chow D; Duquette J; Fox BM; Fu J; Huang X; Houze JB; Jin L; Li Y; Li Z; Ling Y; Lo MC; Long AM; McGee LR; McIntosh J; McMinn DL; Oliner JD; Osgood T; Rew Y; Saiki AY; Shaffer P; Wortman S; Yakowec P; Yan X; Ye Q; Yu D; Zhao X; Zhou J; Olson SH; Medina JC; Sun D
    J Med Chem; 2014 Mar; 57(6):2472-88. PubMed ID: 24548297
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models.
    Tovar C; Graves B; Packman K; Filipovic Z; Higgins B; Xia M; Tardell C; Garrido R; Lee E; Kolinsky K; To KH; Linn M; Podlaski F; Wovkulich P; Vu B; Vassilev LT
    Cancer Res; 2013 Apr; 73(8):2587-97. PubMed ID: 23400593
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design, synthesis and biological evaluation of novel potent MDM2/p53 small-molecule inhibitors.
    Ivanenkov YA; Vasilevski SV; Beloglazkina EK; Kukushkin ME; Machulkin AE; Veselov MS; Chufarova NV; Chernyaginab ES; Vanzcool AS; Zyk NV; Skvortsov DA; Khutornenko AA; Rusanov AL; Tonevitsky AG; Dontsova OA; Majouga AG
    Bioorg Med Chem Lett; 2015 Jan; 25(2):404-9. PubMed ID: 25479770
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oxazoloisoindolinones with in vitro antitumor activity selectively activate a p53-pathway through potential inhibition of the p53-MDM2 interaction.
    Soares J; Pereira NA; Monteiro Â; Leão M; Bessa C; Dos Santos DJ; Raimundo L; Queiroz G; Bisio A; Inga A; Pereira C; Santos MM; Saraiva L
    Eur J Pharm Sci; 2015 Jan; 66():138-47. PubMed ID: 25312347
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discovery of AM-7209, a potent and selective 4-amidobenzoic acid inhibitor of the MDM2-p53 interaction.
    Rew Y; Sun D; Yan X; Beck HP; Canon J; Chen A; Duquette J; Eksterowicz J; Fox BM; Fu J; Gonzalez AZ; Houze J; Huang X; Jiang M; Jin L; Li Y; Li Z; Ling Y; Lo MC; Long AM; McGee LR; McIntosh J; Oliner JD; Osgood T; Saiki AY; Shaffer P; Wang YC; Wortman S; Yakowec P; Ye Q; Yu D; Zhao X; Zhou J; Medina JC; Olson SH
    J Med Chem; 2014 Dec; 57(24):10499-511. PubMed ID: 25384157
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Restoration of p53 using the novel MDM2-p53 antagonist APG115 suppresses dedifferentiated papillary thyroid cancer cells.
    Chen H; Luo D; Zhang L; Lin X; Luo Q; Yi H; Wang J; Yan X; Li B; Chen Y; Liu X; Zhang H; Liu S; Qiu M; Yang D; Jiang N
    Oncotarget; 2017 Jun; 8(26):43008-43022. PubMed ID: 28498808
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MDM2 Inhibition Sensitizes Prostate Cancer Cells to Androgen Ablation and Radiotherapy in a p53-Dependent Manner.
    Feng FY; Zhang Y; Kothari V; Evans JR; Jackson WC; Chen W; Johnson SB; Luczak C; Wang S; Hamstra DA
    Neoplasia; 2016 Apr; 18(4):213-22. PubMed ID: 27108384
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Small-molecule MDM2-p53 inhibitors: recent advances.
    Zhang B; Golding BT; Hardcastle IR
    Future Med Chem; 2015; 7(5):631-45. PubMed ID: 25921402
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design, synthesis and biological evaluation of novel 3,4,5-trisubstituted aminothiophenes as inhibitors of p53-MDM2 interaction. Part 1.
    Wang W; Shangguan S; Qiu N; Hu C; Zhang L; Hu Y
    Bioorg Med Chem; 2013 Jun; 21(11):2879-85. PubMed ID: 23601819
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular rotors as conditionally fluorescent labels for rapid detection of biomolecular interactions.
    Goh WL; Lee MY; Joseph TL; Quah ST; Brown CJ; Verma C; Brenner S; Ghadessy FJ; Teo YN
    J Am Chem Soc; 2014 Apr; 136(17):6159-62. PubMed ID: 24494589
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discovery of a new small-molecule inhibitor of p53-MDM2 interaction using a yeast-based approach.
    Leão M; Pereira C; Bisio A; Ciribilli Y; Paiva AM; Machado N; Palmeira A; Fernandes MX; Sousa E; Pinto M; Inga A; Saraiva L
    Biochem Pharmacol; 2013 May; 85(9):1234-45. PubMed ID: 23428467
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.